July 04, 2009
Home
About
Submit Press Release
PR Firms
Editors/Journalists
Search Archives
 
News Releases by Category  
News by Country  
News by MSA  
All News for Today  
Browse News by Day  
News by Trackbacks  
All Press Releases for April 27, 2005 Subscribe to this News Feed  
 

FOSAMAX and Zometa Side Effects Warning - Victim Compensation

FOSAMAX and Zometa Side Effects. Consumers May Deserve Compensation. Fosamax and Zometa is linked to severe conditions.

(PRWEB) April 27, 2005 -- Fosamax Side Effects Warning - Fosamax and Zometa are a type of drug known as bisphosphonates. Recently a link has been found between bisphosphonates and a serious bone disease called osteonecrosis of the jaw (ONJ). This important discovery clearly shows that Fosamax and Zometa side effects may include osteonecrosis of the jaw, also known as Dead Jaw".

The discovery, published in the Journal of Oral and Maxillofacial Surgeons, prompted both the US, Food and Drug Administration ( FDA ) and Novartis, the manufacturer of bisphosphonates used in cancer chemotherapy, to issue a warning to health care professionals on September 24, 2004. The warning letter contained information about bisphosphonates and the risks of osteonecrosis in the jaw. Bisphosphonates are commonly used in tablet form such as Fosamax ( Alendronate Sodium ) to prevent and treat osteoporosis in post-menopausal women. Stronger forms of bisphosphonates are commonly used in the management of advanced cancers that have metastasized to the bone, where the disease often causes bone pain and possibly even fractures. Several cancers can involve or metastasize to the bone, including lung cancer, breast cancer, prostate cancer, multiple myeloma, and others. When bisphosphonates are given in cancer chemotherapy, the drugs are given intravenously, and usually for longer periods of time.

Osteonecrosis of the Jaw
Osteonecrosis of the jaw ( ONJ ) is a condition in which the bone tissue in the jaw fails to heal after minor trauma such as a tooth extraction, causing the bone to be exposed. The exposure can eventually lead to infection and fracture and may require long-term antibiotic therapy or surgery to remove the dying bone tissue. Experts say that prevention and early treatment of individuals using bisphosphonates such as Fosamax is extremely important in preserving the jaw bone. Individuals using Fosomax or other bisphosphonates should attempt to avoid tooth extractions and other major dental work while on the drugs.

Although most cases of osteonecrosis of the jaw related to Fosamax side effects have occured after dental work several cases have been reported to occur without any prior dental work. Patients taking Fosamax may be at risk of developing osteonecrosis. Patients injured by Fosamax side effects may be entitled to compensation. For more information about the legal rights of patients contact the offices of

Powell Law Firm, L.C.
is the nation's leading law firm
for litigation regarding Bisphosphonate Complications.

for your free, confidential case evaluation
at toll-free 888-238-1998
Please state your name and phone number
And we will get back with you promptly
or email us at
info@mpowelllaw.com

www.MPowellLaw.com

Accepting Inquiries from the U.S. and Internationally

Every case is different. No specific results are implied.

  • South Beverly Drive, Suite 1156, Beverly Hills, CA 90212


See the original story at: http://www.prweb.com/releases/2005/04/prweb233147.htm
Email this story to a colleague
Printer Friendly Version
Bookmark with del.icio.us
Bookmark with Y!MyWeb
Submit to Digg
Powell Law Firm
Powell Law Firm
888-238-1998
Email us Here

There are no multimedia files attached to this release. If this is your release you may add images or other multimedia files through your login.

If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2007, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright